BIOtronik Study to Assess the CONTINUation of Existing Risk of Ventricular Arrhythmias After CRT-D Replacement for Patients With Primary Prevention Indication
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Cardiac Resynchronization
- Sponsor
- Biotronik SE & Co. KG
- Enrollment
- 289
- Locations
- 37
- Primary Endpoint
- Assess the rate of patients with at least one sustained VTA after replacement
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Cardiac resynchronization therapy (CRT) has been shown to reduce heart failure (HF), hospitalizations and death in patients with left ventricular ejection fraction (LVEF) <35% and wide QRS. CRT provides electromechanical resynchronization and improves LV systolic function. The induced LV reverse remodeling or near normalization in LVEF to ≥45% is associated with a significant reduction in the risk of subsequent life-threatening ventricular tachyarrhythmias (VTA). And at the time of replacement, the need for defibrillator back-up after an event-free first CRT-D service-life for patients with improved LVEF is a controversy question.
80% of Implantable Cardioverter Defibrillator (ICD) patients implanted for primary prevention do not experience VTA during the life-time of their first device.
So, regarding patients implanted with a CRT-D for primary prevention at the time of first implantation, the question is will they experience VTA after their device replacement by another CRT-D.
Detailed Description
The objective of this study is to describe, in a population of patients who had a primary prevention ICD indication at first implantation of a CRT-D, the relevance defibrillator back-up after the replacement of the first CRT-D. For that, the rate of patients with at least one sustained VTA detected by the CRT-D or a conventional surface ECG will be assessed after the device replacement. Furthermore, the association between the baseline characteristics of the CRT-D population after replacement and the risk of subsequent VTA will be explored after a minimum of two years FU.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with primary prevention indication for defibrillation at the time of the first CRT-D implantation
- •Patient implanted as first replacement by a CRT-D device (CRT-D by CRT-D)
- •Lifetime of the previous CRT-D \> 3 years
- •Patient willing and able to comply with the protocol and who has provided written informed consent
- •Patient whose medical situation is stable.
Exclusion Criteria
- •Patient with an ICD lead under advisory (e.g. Fidelis lead)
- •Right or left ventricular leads exchange during CRT-D replacement
- •Non functional atrial (except for patient with chronic AF) or right/left ventricular leads
- •Life expectancy \< 1 year
- •Age \< 18 years
- •Pregnant woman or woman who plan to become pregnant during the trial
- •Participation in another interventional clinical study
Outcomes
Primary Outcomes
Assess the rate of patients with at least one sustained VTA after replacement
Time Frame: up to two years
Secondary Outcomes
- Rate of patients with at least one VTA for 4 specific subgroups(After the device replacement and after a minimum of two years follow-up (FU))